AI Consensus Investment Thesis
Gilead Sciences (GILD) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
Buy & Hold
Multiple horizons support ownership with measured follow-through.
1-Year
BUY$147
+8.0%+10.6% incl. dividends5-Year
BUY$194
+42.8%+61.2% incl. dividendsLatest flagship insight
Why the Market Miscalculates the Longevity of This Virology Giant's Moat
There is high consensus that the market systematically misprices this asset's long-acting virology transition and extended patent protection. While near-term acquisitions distort reported earnings, the primary driver remains robust free cash flow generation, while regulatory pricing pressure acts as the main friction.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The asset represents a highly resilient defensive compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry positioned to outperform in a stagflationary macro regimestagflationary macro regimeA persistent macroeconomic environment combining weak growth with persistent inflation.View full glossary entry characterized by elevated interest rates and sticky inflation. The core investment thesis centers on the structural transition of its dominant virology franchise from daily oral regimens to long-acting injectables, which effectively extends the patent runway and neutralizes generic erosiongeneric erosionThe loss of market share and revenue as patents expire and cheaper generic alternatives enter the market.View full glossary entry. While recent high-premium acquisitions and in-process research and development charges temporarily distort reported GAAP earnings, the underlying free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry engine remains pristine, supported by an asset-light operating model and elite gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry.
Key insights
- Legally secured patent settlements extend the core virology franchise exclusivity, providing a highly predictable cash flow floor.
- The commercial ramp of long-acting injectables expands the preventative total addressable markettotal addressable marketTotal addressable market (TAM) is the full revenue opportunity available if a product or service achieved complete adoption within its relevant market.View full glossary entry by solving patient compliance bottlenecks.
- High capital efficiencycapital efficiencyHow much value or profit is produced for each unit of invested capital.View full glossary entry and minimal physical capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry requirements insulate the asset from rising interest rates and inflationary pressures.
- Strategic oncology expansion diversifies the revenue base, though historical high-premium acquisitions introduce capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry risks.
- Regulatory pricing frameworks and federal drug price negotiations present persistent headwinds to net realized margins.
- Robust free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry supports aggressive share repurchases and consistent dividend growth, establishing a strong valuation floorvaluation floorA price or valuation level believed to have durable support from cash flows, assets, policy, or demand.View full glossary entry.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The conventional market narrative views the asset as a stagnant, low-growth cash cow heavily dependent on its legacy daily HIV treatments. The crowd is highly focused on the impending patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry and remains skeptical of the company's expensive pivot into oncology, pointing to recent clinical trial setbacks as evidence of capital destructioncapital destructionA lasting loss of invested capital caused by poor returns, impairment, dilution, or uneconomic investment.View full glossary entry. Consequently, mainstream analysts and retail investors treat the stock as a value trapvalue trapA stock that appears cheap based on valuation metrics but remains stagnant due to fundamental business deterioration.View full glossary entry or a glorified bond proxybond proxyAn equity or other asset valued partly for stable income and therefore often sensitive to changes in bond yields.View full glossary entry, anchoring on optical GAAP losses from recent acquisition write-offs while assuming the business is incapable of long-term top-line growth.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the market's systematic mispricing of the virology franchise's terminal duration and the strategic value of its cash flow. While the crowd fixates on a near-term patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry, legal settlements have quietly extended key patent protections out to 2036. Furthermore, the transition to long-acting injectables represents a compliance paradigm shift that structurally expands the preventative market rather than merely cannibalizing existing sales. In a restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry, the company's massive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry acts as a predatory weapon, allowing it to acquire distressed biotech innovation at cycle-trough valuations. The market prices the asset as a decaying annuity, failing to recognize its evolution into an adaptive, highly capitalized compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry.
Repricing Catalyst
What could make the market recognize and close that gap? The primary catalyst to force a market re-rating is the upcoming regulatory decision dates for the once-weekly oral formulation and the sustained commercial scaling of the twice-yearly injectable. As multi-quarter earnings reports quantify the rapid adoption and market expansion of these long-acting options, sell-side analysts will be forced to aggressively revise their long-term revenue models. This undeniable commercial execution, coupled with potential clinical data readouts validating the oncology pipelineoncology pipelineOncology pipeline refers to the portfolio of cancer-related drug candidates, programs, or studies progressing through research and development stages.View full glossary entry, will dismantle the value-trap narrative and compel the market to re-rate the asset as a premium defensive compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Mixed
- Volatility
- Low Steady
- Cycle position
- Growing Awareness
While there is strong agreement on the low-volatility nature of the asset's cash flows, sentiment diverges regarding the speed of the market's transition. Some perspectives highlight early discovery of the long-acting virology moat, while others suggest a slower stabilization phase as the market digests historical oncology write-offs.
Macro Regime Fit
Does the current market environment support the thesis? The current stagflationary macro regimestagflationary macro regimeA persistent macroeconomic environment combining weak growth with persistent inflation.View full glossary entry, characterized by sticky inflation, elevated interest rates, and geopolitical volatility, serves as a powerful tailwind. In an environment where high capital costs penalize speculative, long-duration growth equities, institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry naturally rotates toward defensive, cash-rich sanctuaries. The asset's highly inelastic demandinelastic demandDemand that changes proportionally less than price over a defined range and period.View full glossary entry profile, elite gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry, and self-funding capital structurecapital structureThe mix of debt and equity used to finance a business.View full glossary entry insulate it from energy shocksenergy shockA sudden disruption or price change in energy markets that affects inflation, demand, and operating costs.View full glossary entry and credit-cycle stress, making it an ideal safe harbor for capital preservation.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across the reports centers on the valuation and return on investment of the oncology pipelineoncology pipelineOncology pipeline refers to the portfolio of cancer-related drug candidates, programs, or studies progressing through research and development stages.View full glossary entry. Some perspectives view historical acquisitions as value-destroying write-offs that will permanently drag on returns, while others argue that these assets are successfully establishing a critical secondary growth engine. Additionally, there is minor divergence regarding the timing of the market's re-rating, with assumptions split between near-term regulatory catalysts and a slower, macro-driven defensive rotation.
Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Lenacapavir HIV Lifecycle Reset | Innovation And Product | +20% | +15% | The commercial rollout of twice-yearly injectables and pending weekly oral formulations represents a fundamental paradigm shift in HIV prevention and treatment. By eliminating daily adherence barriers, this product cycle structurally expands the total addressable markettotal addressable marketTotal addressable market (TAM) is the full revenue opportunity available if a product or service achieved complete adoption within its relevant market.View full glossary entry to higher-risk populations. This transition secures long-term, high-margin recurring revenuerecurring revenueRevenue expected to repeat under subscriptions, contracts, renewals, or recurring customer usage.View full glossary entry streams that will drive top-line growth throughout the forecast horizon, effectively neutralizing generic competition. |
| Extended Patent Protection | Competitive Positioning | +18% | +12% | Legal settlements extending Biktarvy's patent exclusivity to 2036 fundamentally dismantle the near-term generic cliff narrative that has depressed the valuation. This secures nearly a decade of unencumbered monopoly cash flows, providing a highly predictable baseline for valuation models. Analysts must mechanically revise their long-term discounted cash flow models upward to account for these additional years of peak-margin revenue. |
| Defensive Cash Flow and Macro Rotation | Macroeconomic And Macrofinancial | +12% | +5.0% | In a stagflationarystagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry, high-rate environment, the asset's inelastic demandinelastic demandDemand that changes proportionally less than price over a defined range and period.View full glossary entry and massive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry act as a powerful capital magnet. Generating robust cash yields with zero credit-cycle sensitivity drives institutional rotation away from speculative growth toward defensive havens. This structural capital flow supports multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry as investors seek shelter from broader macroeconomic volatility and energy-driven inflation shocks. |
| Predatory Capital Allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry | Capital Allocation | +10% | +8.0% | Armed with substantial annual free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, the company is uniquely positioned to execute accretive, distressed acquisitions of late-stage biotech assets during a capital-starved market cycle. This predatory capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry strategy allows the firm to convert legacy cash into future high-margin pipelines at cycle-trough valuations, effectively bridging the valuation gapvaluation gapThe difference between a market price and an analyst's estimate of intrinsic value.View full glossary entry across upcoming patent transitions. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Regulatory Price Controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry | Regulatory | -10% | -10% | Federal drug pricing negotiations, including the Inflation Reduction Act and populist pricing frameworks, introduce structural caps on net price realization. This regulatory frictionregulatory frictionCost, delay, or uncertainty created by regulatory approval, compliance, supervision, or changing rules.View full glossary entry limits peak operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry and compresses long-term terminal growth assumptions. The constant threat of mandated discounts and political headline risk forces analysts to apply a persistent risk discount to future cash flow models. |
| Historical Capital Allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry Skepticism | Management And Governance | -8.0% | -5.0% | A track record of high-premium, value-destroying oncology acquisitions leaves a persistent scar on institutional trust. The market applies a holding discount to the multiple, fearing future undisciplined M&A deals that could impair return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry. Until management demonstrates sustained discipline in returning capital over empire-building, this governance overhang will artificially suppress the valuation. |
| Oncology Pipelineoncology pipelineOncology pipeline refers to the portfolio of cancer-related drug candidates, programs, or studies progressing through research and development stages.View full glossary entry Attrition | Innovation And Product | -6.0% | -6.0% | Recent clinical trial failures in major solid tumor indications restrict the addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry for flagship oncology assets. This clinical attrition forces reliance on smaller niches, limiting the speed of revenue diversification away from the core virology business. It also requires write-offs of acquired goodwill, acting as a persistent drag on the aggregate return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry. |
| Geopolitical Supply Chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry Decoupling | Political And Geopolitical | -4.0% | -4.0% | Geopolitical fragmentationgeopolitical fragmentationStructural shifts in global trade and policy impacting international business operations and market access.View full glossary entry and legislative mandates require a costly rewiring of manufacturing and clinical supply chains away from China-linked providers. This transition introduces operational friction, elevates near-term cost of goods soldcost of goods soldCost of goods sold (COGS) represents the direct costs of producing or delivering the goods sold by a business.View full glossary entry, and temporarily stresses manufacturing scale-up timelines. While the company has the scale to absorb these costs, it degrades near-term operational efficiencyoperational efficiencyThe ability to produce an intended output or service with minimal waste, delay, or cost.View full glossary entry. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Draconian Federal Price Caps | 20% | -25% | Regulatory | Extreme populist legislative reforms imposing retroactive, hard price caps on specialty therapeutics would structurally destroy the gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry architecture. This regulatory expropriation would severely impair free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, dismantle the company's capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry capacity, and force a brutal downward repricing. Because the stock is valued on owner earningsowner earningsAn estimate of cash available to owners after operating costs, taxes, and the capital spending needed to maintain competitive capacity.View full glossary entry, a permanent legislative impairment would shatter the margin of safetymargin of safetyThe difference between an estimated intrinsic value and the purchase price, intended to allow for uncertainty or analytical error.View full glossary entry. |
| Long-Acting Safety Signal Emergence | 15% | -20% | Innovation And Product | The emergence of severe, delayed real-world safety issues with long-acting injectable formulations would instantly vaporize the primary growth thesis. Because these therapeutics persist in the body for months, managing adverse events is highly complex, risking severe label restrictions or product withdrawals. This would leave the company completely exposed to generic competition without a pipeline replacement. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Breakthrough in Solid Tumor CAR-T | 25% | +20% | Innovation And Product | Successful clinical validation of cell therapies in major solid tumor indications would unlock an exponentially larger addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry than blood cancers. This breakthrough would trigger immediate multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry, shifting the asset's narrative from a stagnant virology proxy to a high-growth oncology pioneer. Although a low-probability event, it represents massive convex upside that is completely unpriced by the market. |
| Distressed Biotech Consolidation | 35% | +12% | Capital Allocation | A prolonged high-rate environment could force cash-starved, high-quality biotech firms into insolvency, allowing the company to acquire de-risked, late-stage clinical assets at fire-sale valuations. By plugging these assets into its global commercial infrastructure, the firm would immediately bridge its patent cliffs and establish a permanent secondary moat, driving a dominant market re-rating. |
Company Financial Analysis
Gilead Sciences Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The consensus shows that the company's financial engine is incredibly strong and recovering rapidly. After a temporary drop in reported profits in 2024 due to one-time acquisition costs, earnings bounced back sharply in 2025, with annual free cash flow consistently exceeding ten billion dollars. While overall revenue growth is slow and steady, the company's ability to turn sales into actual cash is outstanding. There is broad agreement that this massive cash flow provides a powerful safety net during economic downturns. However, opinions differ on the future growth path: some expect steady, flat performance as older products face competition, while others anticipate a growth breakout as new treatments hit the market. Overall, the financial health is highly supportive, offering retail investors a reliable, low-risk cash generator.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 29.4B | USD 8.5B | USD 9.5B |
| 2024 | USD 28.8B | USD 480M | USD 10.3B |
| 2023 | USD 27.1B | USD 5.7B | USD 7.4B |
| 2022 | USD 27.3B | USD 4.6B | USD 8.3B |
| 2021 | USD 27.3B | USD 6.2B | USD 10.8B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 18.1x | TTM | Native | USD / USD |
| 2024 | >100x | TTM | Native | USD / USD |
| 2023 | 18.0x | TTM | Native | USD / USD |
| 2022 | 23.6x | Annual | Native | USD / USD |
| 2021 | 14.7x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company boasts elite profitability, highlighted by gross margins near eighty percent, which reflects its immense pricing power and the low cost of producing its core medicines. Operating margins have normalized around a robust forty percent after recovering from past acquisition write-offs. Analysts agree that these high margins provide a strong buffer against inflation and rising business costs. However, there is a clear clash of opinions regarding future margin trends. Some warn that government price negotiations and political pressure to lower drug costs will inevitably squeeze profit margins over time. Others argue that the high-margin nature of new long-acting treatments will easily offset these regulatory pressures. Overall, the margin profile remains a key structural advantage, protecting real earnings power in a challenging economic environment.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 11.7B | 39.7% | 28.9% |
| 2024 | USD 1.7B | 5.8% | 1.7% |
| 2023 | USD 7.6B | 28.0% | 20.9% |
| 2022 | USD 7.3B | 26.9% | 16.8% |
| 2021 | USD 9.9B | 36.3% | 22.8% |
Balance sheet and leverage
The company's balance sheet is a verified financial fortress, recently upgraded by major rating agencies. With manageable debt levels and an exceptional ability to cover its interest payments, the business is highly insulated from rising interest rates and credit market stress. Analysts universally agree that this financial strength provides excellent downside protection, ensuring the company can easily pay its attractive dividend and continue buying back its own shares. Furthermore, this strong position gives the company the financial firepower to make opportunistic purchases of smaller, struggling biotech firms during market downturns. There is virtually no disagreement on the safety of the balance sheet, making it a highly reliable anchor for conservative investors seeking capital preservation in a volatile market.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 24.6B | USD 10.6B | USD 17B net debt | 1.68x |
| 2024 | USD 26.7B | USD 11.6B | USD 16.7B net debt | 1.60x |
| 2023 | USD 25B | USD 7.3B | USD 18.9B net debt | 1.43x |
| 2022 | USD 25.2B | USD 6.4B | USD 19.8B net debt | 1.29x |
| 2021 | USD 26.7B | USD 6.5B | USD 21.4B net debt | 1.27x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company operates an extremely capital-light business, spending less than two percent of its revenue on physical buildings and equipment. Instead, its true investment focus is on research and development, where it spends nearly six billion dollars annually to develop new drugs and protect its market position. Analysts agree that this low physical spending is a major advantage because it leaves more cash available for dividends and stock buybacks. However, there is some disagreement regarding the company's heavy spending on acquisitions. Some view these multi-billion-dollar purchases as necessary to replace older drugs before their patents expire, while others worry that the company is overpaying for unproven technologies. Monitoring how efficiently these investments turn into profitable new treatments remains key for long-term investors.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 563M | USD 5.8B |
| 2024 | USD 523M | USD 5.9B |
| 2023 | USD 585M | USD 5.7B |
| 2022 | USD 728M | USD 5B |
| 2021 | USD 579M | USD 4.6B |
Quarterly Forecast Scenarios
Gilead Sciences Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $133.90 | $135.54 | $137.83 | $736.09 | |
| $132.56 | $139.39 | $143.35 | $724.14 | |
| $133.83 | $142.66 | $149.08 | $713.57 | |
| $139.18 | $146.58 | $155.02 | $723.38 | |
| $136.48 | $148.05 | $158.12 | $716.61 | |
| $137.71 | $150.90 | $162.86 | $738.34 | |
| $144.59 | $154.63 | $166.16 | $746.91 | |
| $147.48 | $156.76 | $169.49 | $771.93 | |
| $148.96 | $160.00 | $172.81 | $782.73 | |
| $143.00 | $161.81 | $172.74 | $807.31 | |
| $147.29 | $164.03 | $177.92 | $822.72 | |
| $153.18 | $168.10 | $181.48 | $846.10 | |
| $151.88 | $171.33 | $185.11 | $852.53 | |
| $153.12 | $174.47 | $190.66 | $882.91 | |
| $157.71 | $177.25 | $191.97 | $900.46 | |
| $164.02 | $178.80 | $192.53 | $922.67 | |
| $162.38 | $182.30 | $196.38 | $935.91 | |
| $167.25 | $186.07 | $202.27 | $952.30 | |
| $170.60 | $189.45 | $207.57 | $976.28 | |
| $172.61 | $193.89 | $211.72 | $1,002 |
Research Provenance
References & Context
This Gilead Sciences consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2007-01-01–2026-01-01, 20 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).